Published in Rheumatology (Oxford) on July 31, 2010
Initiation of tumor necrosis factor-α antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. JAMA (2011) 3.58
Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis. Lancet (2015) 3.38
Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient? Ann Rheum Dis (2011) 2.67
Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease. Ann Rheum Dis (2012) 2.29
Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis (2012) 1.56
Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis (2012) 1.54
Safety of biologic therapy in rheumatoid arthritis. Nat Rev Rheumatol (2011) 1.22
Putting together the psoriasis puzzle: an update on developing targeted therapies. Dis Model Mech (2012) 1.09
Tocilizumab in patients with active rheumatoid arthritis and inadequate responses to DMARDs and/or TNF inhibitors: a large, open-label study close to clinical practice. Ann Rheum Dis (2012) 1.08
Development and validation of a risk score for serious infection in patients with rheumatoid arthritis. Arthritis Rheum (2012) 1.03
Older age is associated with higher rate of discontinuation of anti-TNF therapy in patients with inflammatory bowel disease. Inflamm Bowel Dis (2013) 1.03
A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis (2015) 1.01
Harms of TNF inhibitors in rheumatic diseases: a focused review of the literature. Immunotherapy (2013) 0.99
Rates of, and risk factors for, severe infections in patients with systemic autoimmune diseases receiving biological agents off-label. Arthritis Res Ther (2011) 0.93
Management of rheumatoid arthritis: consensus recommendations from the Hong Kong Society of Rheumatology. Clin Rheumatol (2010) 0.90
Risk of infections associated with biological treatment in inflammatory bowel disease. World J Gastroenterol (2014) 0.90
Infection risk in rheumatoid arthritis and spondyloarthropathy patients under treatment with DMARDs, corticosteroids and TNF-α antagonists. J Transl Med (2014) 0.90
Update on the safety profile of certolizumab pegol in rheumatoid arthritis: an integrated analysis from clinical trials. Ann Rheum Dis (2013) 0.90
Evaluation of the RABBIT Risk Score for serious infections. Ann Rheum Dis (2013) 0.89
Physicians' explanations for apparent gaps in the quality of rheumatology care: results from the US Medicare Physician Quality Reporting System. Arthritis Care Res (Hoboken) (2013) 0.88
Efficacy and safety of golimumab as add-on therapy to disease-modifying antirheumatic drugs: results of the GO-MORE study. Ann Rheum Dis (2013) 0.87
Transcriptional profile of tuberculosis antigen-specific T cells reveals novel multifunctional features. J Immunol (2014) 0.86
TNF signals via neuronal-type nitric oxide synthase and reactive oxygen species to depress specific force of skeletal muscle. J Appl Physiol (1985) (2013) 0.86
Should anti-TNF therapy be discontinued in rheumatoid arthritis patients undergoing elective orthopaedic surgery? A systematic review of the evidence. Rheumatol Int (2011) 0.86
Definition of CD4 Immunosignatures Associated with MTB. Front Immunol (2014) 0.85
The influence of ageing on the development and management of rheumatoid arthritis. Nat Rev Rheumatol (2013) 0.85
QuantiFERON-TB Gold In-Tube assay for screening arthritis patients for latent tuberculosis infection before starting anti-tumor necrosis factor treatment. PLoS One (2015) 0.84
[Recommendations of the German Society for Rheumatology on the perioperative approach under therapy with DMARDs and biologicals in inflammatory rheumatic diseases]. Z Rheumatol (2014) 0.83
Safety and effectiveness of adalimumab in patients with rheumatoid arthritis over 5 years of therapy in a phase 3b and subsequent postmarketing observational study. Arthritis Res Ther (2014) 0.82
The importance of rheumatology biologic registries in Latin America. Rheumatol Int (2012) 0.82
Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials. Ann Rheum Dis (2017) 0.82
Anncaliia algerae microsporidial myositis. Emerg Infect Dis (2014) 0.82
Safety of tumor necrosis factor inhibitors use for rheumatoid arthritis and ankylosing spondylitis in Africa, the Middle East, and Asia: focus on severe infections and tuberculosis. Clin Rheumatol (2012) 0.81
HBV Reactivation in Patients Treated with Antitumor Necrosis Factor-Alpha (TNF-α) Agents for Rheumatic and Dermatologic Conditions: A Systematic Review and Meta-Analysis. Int J Rheumatol (2014) 0.81
Medically Significant Infections Are Increased in Patients With Juvenile Idiopathic Arthritis Treated With Etanercept: Results From the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study. Arthritis Rheumatol (2015) 0.81
Comparison of tuberculosis incidence in ankylosing spondylitis and rheumatoid arthritis during tumor necrosis factor inhibitor treatment in an intermediate burden area. Clin Rheumatol (2013) 0.81
Adalimumab long-term safety: infections, vaccination response and pregnancy outcomes in patients with rheumatoid arthritis. Ann Rheum Dis (2016) 0.80
Efficacy and Safety of Subcutaneous Golimumab in Methotrexate-Naive Patients With Rheumatoid Arthritis: Five-Year Results of a Randomized Clinical Trial. Arthritis Care Res (Hoboken) (2016) 0.80
Peripheral administration of the selective inhibitor of soluble tumor necrosis factor (TNF) XPro®1595 attenuates nigral cell loss and glial activation in 6-OHDA hemiparkinsonian rats. J Parkinsons Dis (2014) 0.80
Older age and steroid use are associated with increasing polypharmacy and potential medication interactions among patients with inflammatory bowel disease. Inflamm Bowel Dis (2015) 0.80
Targeting Low Disease Activity in Elderly-Onset Rheumatoid Arthritis: Current and Future Roles of Biological Disease-Modifying Antirheumatic Drugs. Drugs Aging (2016) 0.79
Determinants of Risk Infection During Therapy with Anti TNF-Alpha Blocking Agents in Rheumatoid Arthritis. Open Rheumatol J (2012) 0.79
Anti-TNF therapy in Jordan: a focus on severe infections and tuberculosis. Biologics (2014) 0.79
[The safety of biologics : a risk-benefit assessment of treating rheumatoid arthritis with biologics based on registry data on mortality]. Z Rheumatol (2010) 0.78
Histone Deacetylase Inhibitors Promote Mitochondrial Reactive Oxygen Species Production and Bacterial Clearance by Human Macrophages. Antimicrob Agents Chemother (2015) 0.78
Serious infections in patients with rheumatoid arthritis and other immune-mediated connective tissue diseases exposed to anti-TNF or rituximab: data from the Spanish registry BIOBADASER 2.0. Rheumatol Int (2014) 0.78
Rituximab impairs immunoglobulin (Ig)M and IgG (subclass) responses after influenza vaccination in rheumatoid arthritis patients. Clin Exp Immunol (2014) 0.78
[How do register data support clinical decision-making?]. Z Rheumatol (2015) 0.78
Biologics Prescribing for Rheumatoid Arthritis in Older Patients: A Single-Center Retrospective Cross-Sectional Study. Rheumatol Ther (2015) 0.77
Hardware Removal Due to Infection after Open Reduction and Internal Fixation: Trends and Predictors. Arch Bone Jt Surg (2015) 0.77
Safety of Adalimumab and Predictors of Adverse Events in 1693 Japanese Patients with Crohn's Disease. J Crohns Colitis (2016) 0.77
Infections associated with monoclonal antibody and fusion protein therapy in humans. MAbs (2011) 0.77
Older age at rheumatoid arthritis onset and comorbidities correlate with less Health Assessment Questionnaire-Disability Index and Clinical Disease Activity Index response to etanercept in the RADIUS 2 registry. J Clin Rheumatol (2014) 0.76
Anti-inflammatory effect of a retrovirus-derived immunosuppressive peptide in mouse models. BMC Immunol (2013) 0.75
Mortality in patients with rheumatoid arthritis: a 15-year prospective cohort study. Rheumatol Int (2016) 0.75
Haemanthus coccineus extract and its main bioactive component narciclasine display profound anti-inflammatory activities in vitro and in vivo. J Cell Mol Med (2015) 0.75
Infective endocarditis following tumor necrosis factor-α antagonist therapy for management of psoriatic erythroderma: a case report. J Med Case Rep (2017) 0.75
Incidence density of serious infection, opportunistic infection, and tuberculosis associated with biologic treatment in patients with rheumatoid arthritis - a systematic evaluation of the literature. Open Access Rheumatol (2013) 0.75
Comparative risk of hospitalized infection between biological agents in rheumatoid arthritis patients: A multicenter retrospective cohort study in Japan. PLoS One (2017) 0.75
Hepatitis B Serology in Patients with Rheumatic Diseases. Open Rheumatol J (2016) 0.75
The safety of systemic treatments that can be used for geriatric psoriasis patients: a review. Dermatol Res Pract (2012) 0.75
Epidemiology research in rheumatology-progress and pitfalls. Nat Rev Rheumatol (2015) 0.75
Drug retention and safety of TNF inhibitors in elderly patients with rheumatoid arthritis. BMC Musculoskelet Disord (2016) 0.75
Chronotherapy with low-dose modified-release prednisone for the management of rheumatoid arthritis: a review. Ther Clin Risk Manag (2016) 0.75
Decreased use of glucocorticoids in biological-experienced patients with rheumatoid arthritis who initiated intravenous abatacept: results from the 2-year ACTION study. RMD Open (2016) 0.75
Impact of treatment with biologic DMARDs on the risk of sepsis or mortality after serious infection in patients with rheumatoid arthritis. Ann Rheum Dis (2015) 0.75
Effectiveness and safety of TNF inhibitors in adults with juvenile idiopathic arthritis. RMD Open (2016) 0.75
Septic arthritis in the era of immunosuppressive treatments. Ann R Coll Surg Engl (2014) 0.75
Effect of tocilizumab on neutrophils in adult patients with rheumatoid arthritis: pooled analysis of data from phase 3 and 4 clinical trials. Rheumatology (Oxford) (2016) 0.75
Both anti-TNF and CTLA4 Ig treatments attenuate the disease severity of staphylococcal dermatitis in mice. PLoS One (2017) 0.75
The BSRBR-RA at 15 years. Rheumatology (Oxford) (2016) 0.75
Long-term use of biologic agents does not increase the risk of serious infections in elderly patients with rheumatoid arthritis. Rheumatol Int (2016) 0.75
Risk of Serious Infections in Patients with Psoriasis on Biologic Therapies: A Systematic Review and Meta-Analysis. J Invest Dermatol (2016) 0.75
Rheumatoid arthritis - an update for general dental practitioners. Br Dent J (2016) 0.75
Managing the drug treatment of rheumatoid arthritis. Aust Prescr (2017) 0.75
The role of adalimumab in rheumatic and autoimmune disorders: comparison with other biologic agents. Open Access Rheumatol (2012) 0.75
Inhibiting TNF-α signaling does not attenuate induction of endotoxin tolerance. J Inflamm Res (2014) 0.75
Effect of Anti-TNF Antibodies on Clinical Response in Rheumatoid Arthritis Patients: A Meta-Analysis. Biomed Res Int (2016) 0.75
[Prophylaxis and treatment of infections in elderly patients with rheumatism]. Z Rheumatol (2014) 0.75
Spinal non-Hodgkin's lymphoma mimicking a flare of disease in a patient with ankylosing spondylitis treated with anti-TNF agents: case report and review of the literature. Clin Rheumatol (2014) 0.75
QuantiFERON testing for cell-mediated immunity to cytomegalovirus in patients with rheumatoid arthritis receiving abatacept and other DMARD therapy. Clin Rheumatol (2013) 0.75
Urinary free light chains may help to identify infection in patients with elevated systemic inflammation due to rheumatic disease. Rheumatol Int (2017) 0.75
Biologics registers in RA: methodological aspects, current role and future applications. Nat Rev Rheumatol (2017) 0.75
[Bacterial septic arthritis as rheumatological emergency]. Z Rheumatol (2012) 0.75
Real-life 10-year retention rate of first-line anti-TNF drugs for inflammatory arthritides in adult- and juvenile-onset populations: similarities and differences. Clin Rheumatol (2017) 0.75
[Periprosthetic infections in systemic inflammatory rheumatic disease. Review article on diagnostics and therapy]. Z Rheumatol (2014) 0.75
Incidence of comprehensive hospitalization due to infection, cardiovascular disease, fractures, and malignancies in patients with rheumatoid arthritis. Rheumatol Int (2017) 0.75
Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol (2003) 10.29
Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol (2001) 5.59
Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum (2002) 4.69
Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum (2005) 4.64
Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum (2006) 4.20
Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA (2009) 3.90
Predictors of infection in rheumatoid arthritis. Arthritis Rheum (2002) 3.47
Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. Arthritis Rheum (2006) 3.16
Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis (2009) 2.65
Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists. Ann Rheum Dis (2007) 2.53
Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. Arthritis Rheum (2007) 2.37
The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events. Ann Rheum Dis (2008) 2.36
Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: comparison of patients according to their eligibility for major randomized clinical trials. Arthritis Rheum (2006) 2.28
Longterm mortality outcome in patients with rheumatoid arthritis: early presenters continue to do well. J Rheumatol (1998) 2.00
Anti-tumor necrosis factor therapy in sepsis: update on clinical trials and lessons learned. Crit Care Med (2001) 1.96
Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry. Ann Rheum Dis (2009) 1.70
The British Society for Rheumatology biologics register. Ann Rheum Dis (2005) 1.66
The safety of anti-tumour necrosis factor therapy in rheumatoid arthritis. Curr Opin Rheumatol (2008) 1.64
Infection in rheumatoid arthritis. Arthritis Rheum (1971) 1.44
Use of nonbiologic disease-modifying antirheumatic drugs and risk of infection in patients with rheumatoid arthritis. Arthritis Rheum (2008) 1.33
TNF receptors in murine Candida albicans infection: evidence for an important role of TNF receptor p55 in antifungal defense. J Immunol (1996) 1.24
Tolerance and effectiveness of anti-tumor necrosis factor alpha therapies in elderly patients with rheumatoid arthritis: a population-based cohort study. Arthritis Rheum (2007) 1.13
Initiation of rheumatoid arthritis treatments and the risk of serious infections. Rheumatology (Oxford) (2009) 1.10
Response to etanercept (Enbrel) in elderly patients with rheumatoid arthritis: a retrospective analysis of clinical trial results. J Rheumatol (2003) 1.08
Exacerbation of murine Pneumocystis carinii infection by adenoviral-mediated gene transfer of a TNF inhibitor. Am J Respir Cell Mol Biol (1997) 1.04
Safety and efficacy of etanercept treatment in elderly subjects with rheumatoid arthritis. J Rheumatol (2006) 1.03
Early rheumatoid arthritis patients: relationship of age. Rheumatol Int (2002) 0.95
Experimental therapies for sepsis directed against tumour necrosis factor. J Antimicrob Chemother (1998) 0.87
Enhancement of immune complex clearance by TNF-alpha in a murine model. Clin Immunol Immunopathol (1998) 0.85
Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat Genet (2007) 12.62
Genome-wide association study of CNVs in 16,000 cases of eight common diseases and 3,000 shared controls. Nature (2010) 12.27
Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol (2012) 4.52
Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum (2006) 4.20
Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum (2007) 3.99
Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) (2006) 3.73
Mortality in early inflammatory polyarthritis: cardiovascular mortality is increased in seropositive patients. Arthritis Rheum (2002) 3.53
Human SNP links differential outcomes in inflammatory and infectious disease to a FOXO3-regulated pathway. Cell (2013) 3.49
Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum (2007) 3.34
Measuring disease prevalence: a comparison of musculoskeletal disease using four general practice consultation databases. Br J Gen Pract (2007) 3.16
The epidemiology of chronic syndromes that are frequently unexplained: do they have common associated factors? Int J Epidemiol (2005) 2.48
Specific interaction between genotype, smoking and autoimmunity to citrullinated alpha-enolase in the etiology of rheumatoid arthritis. Nat Genet (2009) 2.48
Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies. Arthritis Rheum (2007) 2.46
Cognitive behavior therapy, exercise, or both for treating chronic widespread pain. Arch Intern Med (2011) 2.37
Functional and prognostic relevance of the -173 polymorphism of the macrophage migration inhibitory factor gene in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum (2003) 2.20
Dietary risk factors for the development of inflammatory polyarthritis: evidence for a role of high level of red meat consumption. Arthritis Rheum (2004) 2.19
Baseline levels of C-reactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyarthritis: a ten-year followup study of a primary care-based inception cohort. Arthritis Rheum (2005) 2.14
Immune reconstitution syndrome to Strongyloides stercoralis infection. AIDS (2007) 2.04
Low back pain in schoolchildren: occurrence and characteristics. Pain (2002) 2.02
Modest association of joint hypermobility with disabling and limiting musculoskeletal pain: results from a large-scale general population-based survey. Arthritis Care Res (Hoboken) (2013) 2.01
Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis (2011) 1.99
The influence of anti-TNF therapy upon incidence of keratinocyte skin cancer in patients with rheumatoid arthritis: longitudinal results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis (2012) 1.80
Prevalence and predictors of intense, chronic, and disabling neck and back pain in the UK general population. Spine (Phila Pa 1976) (2003) 1.79
Risks and benefits of tumor necrosis factor-alpha inhibitors in the management of psoriatic arthritis: systematic review and metaanalysis of randomized controlled trials. J Rheumatol (2008) 1.78
Efficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) (2010) 1.77
No evidence of association between anti-tumor necrosis factor treatment and mortality in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum (2010) 1.73
Pregnancy outcome in women who were exposed to anti-tumor necrosis factor agents: results from a national population register. Arthritis Rheum (2006) 1.72
Lateral wedge insoles as a conservative treatment for pain in patients with medial knee osteoarthritis: a meta-analysis. JAMA (2013) 1.67
Predictors of low back pain in British schoolchildren: a population-based prospective cohort study. Pediatrics (2003) 1.67
Mutation screening of the macrophage migration inhibitory factor gene: positive association of a functional polymorphism of macrophage migration inhibitory factor with juvenile idiopathic arthritis. Arthritis Rheum (2002) 1.66
Different methods of balancing covariates leading to different effect estimates in the presence of effect modification. Am J Epidemiol (2009) 1.60
Observational study of treatment outcome in early diffuse cutaneous systemic sclerosis. J Rheumatol (2009) 1.60
Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis (2012) 1.56
National study of cause-specific mortality in rheumatoid arthritis, juvenile chronic arthritis, and other rheumatic conditions: a 20 year followup study. J Rheumatol (2003) 1.56
BSR and BHPR guidelines on the use of rituximab in rheumatoid arthritis. Rheumatology (Oxford) (2011) 1.55
Genome-wide association study and gene expression analysis identifies CD84 as a predictor of response to etanercept therapy in rheumatoid arthritis. PLoS Genet (2013) 1.54
Factors influencing response to disease modifying antirheumatic drugs in patients with rheumatoid arthritis. J Rheumatol (2005) 1.52
Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: results from the British Society for Rheumatology Biologics Register. Arthritis Care Res (Hoboken) (2010) 1.44
Genome-wide association study of genetic predictors of anti-tumor necrosis factor treatment efficacy in rheumatoid arthritis identifies associations with polymorphisms at seven loci. Arthritis Rheum (2011) 1.44
Changes in disease characteristics and response rates among patients in the United Kingdom starting anti-tumour necrosis factor therapy for rheumatoid arthritis between 2001 and 2008. Rheumatology (Oxford) (2010) 1.43
Incidence of cancer among UK Gulf war veterans: cohort study. BMJ (2003) 1.43
Baseline comorbidity levels in biologic and standard DMARD treated patients with rheumatoid arthritis: results from a national patient register. Ann Rheum Dis (2005) 1.36
The incidence of rheumatoid arthritis in the UK: comparisons using the 2010 ACR/EULAR classification criteria and the 1987 ACR classification criteria. Results from the Norfolk Arthritis Register. Ann Rheum Dis (2012) 1.30
BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies. Rheumatology (Oxford) (2010) 1.30
Predictors of hip joint replacement in new attenders in primary care with hip pain. Br J Gen Pract (2003) 1.29
Active exercise, education, and cognitive behavioral therapy for persistent disabling low back pain: a randomized controlled trial. Spine (Phila Pa 1976) (2007) 1.29
Anti-tumor necrosis factor alpha therapy and the risk of lymphoma in rheumatoid arthritis: no clear answer. Arthritis Rheum (2004) 1.27
Risk and predictors of infection leading to hospitalisation in a large primary-care-derived cohort of patients with inflammatory polyarthritis. Ann Rheum Dis (2006) 1.25
Mortality in established rheumatoid arthritis. Best Pract Res Clin Rheumatol (2007) 1.24
When should the doctor order a spine X-ray? Identifying vertebral fractures for osteoporosis care: results from the European Prospective Osteoporosis Study (EPOS). J Bone Miner Res (2004) 1.24
Anti-TNF therapies and pregnancy: outcome of 130 pregnancies in the British Society for Rheumatology Biologics Register. Ann Rheum Dis (2011) 1.24
Statin use in rheumatoid arthritis in relation to actual cardiovascular risk: evidence for substantial undertreatment of lipid-associated cardiovascular risk? Ann Rheum Dis (2009) 1.22
Factors influencing the antibody response of dogs vaccinated against rabies. Vaccine (2007) 1.22
Serum galectin-2, -4, and -8 are greatly increased in colon and breast cancer patients and promote cancer cell adhesion to blood vascular endothelium. Clin Cancer Res (2011) 1.21
Risk of cancer in patients receiving non-biologic disease-modifying therapy for rheumatoid arthritis compared with the UK general population. Rheumatology (Oxford) (2013) 1.21
Cases of early inflammatory polyarthritis should not be classified as having rheumatoid arthritis. J Rheumatol (2003) 1.20
The validity and responsiveness of generic utility measures in rheumatoid arthritis: a review. J Rheumatol (2008) 1.20